{"filing":{"accession_number":"0001193125-26-347869","cik":"0001657677","ticker":"PBLS","company_name":"Parabilis Medicines, Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"ck0001657677-20260813.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1657677/000119312526347869/ck0001657677-20260813.htm"},"events":[{"id":27489,"run_id":25059,"accession_number":"0001193125-26-347869","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Parabilis Medicines reported Q2 2026 financial results, including a net loss of $52.5M, R\u0026D expenses of $39.4M, G\u0026A expenses of $11.7M, and cash position of $1.1B. The disclosure also included material business updates on zolucatetide advancement and a $125M Regeneron collaboration.","company_name":"Parabilis Medicines, Inc.","ticker":"PBLS","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29055,"accession_number":"0001193125-26-347869","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 financial results. The Item 2.02 disclosure announces quarterly financial results including cash position ($1.1B), R\u0026D expenses ($39.4M), G\u0026A expenses ($11.7M), and net loss ($52.5M), with a press release furnished as Exhibit 99.1. The filing explicitly states \"Parabilis Medicines Reports Second Quarter 2026 Financial Results\" and includes condensed consolidated balance sheets, making this a standard quarterly earnings announcement material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:20:40.922203+00:00","company_name":"","ticker":null,"filing_date":""},{"id":29056,"accession_number":"0001193125-26-347869","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure references an updated corporate presentation, but the supplemental exhibits (EX-99.1) contain a full earnings release for Q2 2026 with detailed financial results, business highlights, and forward-looking guidance. The earnings release reports Q2 2026 financial results including R\u0026D expenses ($39.4M), G\u0026A expenses ($11.7M), net loss ($52.5M), and cash position ($1.1B), along with material business updates on zolucatetide advancement and the $125M Regeneron collaboration. This is a material earnings disclosure for a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:20:40.922203+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29055,"accession_number":"0001193125-26-347869","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 financial results. The Item 2.02 disclosure announces quarterly financial results including cash position ($1.1B), R\u0026D expenses ($39.4M), G\u0026A expenses ($11.7M), and net loss ($52.5M), with a press release furnished as Exhibit 99.1. The filing explicitly states \"Parabilis Medicines Reports Second Quarter 2026 Financial Results\" and includes condensed consolidated balance sheets, making this a standard quarterly earnings announcement material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:20:40.922203+00:00","company_name":"Parabilis Medicines, Inc.","ticker":"PBLS","filing_date":"2026-08-13"},{"id":29056,"accession_number":"0001193125-26-347869","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure references an updated corporate presentation, but the supplemental exhibits (EX-99.1) contain a full earnings release for Q2 2026 with detailed financial results, business highlights, and forward-looking guidance. The earnings release reports Q2 2026 financial results including R\u0026D expenses ($39.4M), G\u0026A expenses ($11.7M), net loss ($52.5M), and cash position ($1.1B), along with material business updates on zolucatetide advancement and the $125M Regeneron collaboration. This is a material earnings disclosure for a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:20:40.922203+00:00","company_name":"Parabilis Medicines, Inc.","ticker":"PBLS","filing_date":"2026-08-13"}]}